[go: up one dir, main page]

MX2018000515A - Compuestos fluorados de cbd, composiciones y usos de los mismos. - Google Patents

Compuestos fluorados de cbd, composiciones y usos de los mismos.

Info

Publication number
MX2018000515A
MX2018000515A MX2018000515A MX2018000515A MX2018000515A MX 2018000515 A MX2018000515 A MX 2018000515A MX 2018000515 A MX2018000515 A MX 2018000515A MX 2018000515 A MX2018000515 A MX 2018000515A MX 2018000515 A MX2018000515 A MX 2018000515A
Authority
MX
Mexico
Prior art keywords
compositions
flourinated
cbd compounds
compounds
cbd
Prior art date
Application number
MX2018000515A
Other languages
English (en)
Inventor
Mechoulam Raphael
Breuer Aviva
Pereira Kapczinski Flavio
Alexandre De Souza Crippa Jose
Waldo Zuardi Antonio
Eduardo Cecilio Hallak Jaime
Silveira Guimaraes Francisco
Original Assignee
Yissum Res Dev Co Of Hebrew Univ Jerusalem Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Yissum Res Dev Co Of Hebrew Univ Jerusalem Ltd filed Critical Yissum Res Dev Co Of Hebrew Univ Jerusalem Ltd
Publication of MX2018000515A publication Critical patent/MX2018000515A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C39/00—Compounds having at least one hydroxy or O-metal group bound to a carbon atom of a six-membered aromatic ring
    • C07C39/24—Halogenated derivatives
    • C07C39/42—Halogenated derivatives containing six-membered aromatic rings and other rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C69/00—Esters of carboxylic acids; Esters of carbonic or haloformic acids
    • C07C69/62—Halogen-containing esters
    • C07C69/63—Halogen-containing esters of saturated acids
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C2601/00—Systems containing only non-condensed rings
    • C07C2601/12—Systems containing only non-condensed rings with a six-membered ring
    • C07C2601/16—Systems containing only non-condensed rings with a six-membered ring the ring being unsaturated

Landscapes

  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Psychiatry (AREA)
  • Pain & Pain Management (AREA)
  • Psychology (AREA)
  • Hospice & Palliative Care (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)

Abstract

La presente invención se relaciona con compuestos CBD sustituidos con flúor, composiciones de los mismos y usos de los mismos para la preparación de medicamentos.
MX2018000515A 2015-07-16 2016-07-15 Compuestos fluorados de cbd, composiciones y usos de los mismos. MX2018000515A (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201562193296P 2015-07-16 2015-07-16
US201562255738P 2015-11-16 2015-11-16
PCT/BR2016/050162 WO2017008136A2 (en) 2015-07-16 2016-07-15 Flourinated cbd compounds, compositions and uses thereof

Publications (1)

Publication Number Publication Date
MX2018000515A true MX2018000515A (es) 2018-09-26

Family

ID=57756615

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2018000515A MX2018000515A (es) 2015-07-16 2016-07-15 Compuestos fluorados de cbd, composiciones y usos de los mismos.

Country Status (8)

Country Link
US (1) US20190084909A1 (es)
EP (1) EP3322411A4 (es)
JP (1) JP2018529636A (es)
CN (1) CN108024973A (es)
AU (1) AU2016293387A1 (es)
CA (1) CA2992494A1 (es)
MX (1) MX2018000515A (es)
WO (1) WO2017008136A2 (es)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2020123250A1 (en) * 2018-12-11 2020-06-18 John Heaney Cannabinoid derivatives and methods for their preparation
WO2020185661A1 (en) * 2019-03-08 2020-09-17 The Regents Of The University Of California Use of 8,9-dihydrocannabidiol compounds
CN111943813B (zh) * 2019-05-17 2023-04-14 上海特化医药科技有限公司 大麻二酚类化合物的制备方法
CN113087741B (zh) * 2020-01-08 2023-04-28 成都百裕制药股份有限公司 大麻二酚衍生物及其制备方法和在医药上的应用
US12486226B2 (en) 2020-01-24 2025-12-02 Revvity Health Sciences, Inc. Cannabinoid derivatives
US20230218213A1 (en) * 2020-07-02 2023-07-13 The Johns Hopkins University Fmri-hippocampus acoustic battery (fhab)
CN114507153B (zh) * 2020-11-17 2025-06-24 中国科学院上海药物研究所 一类间苯二酚化合物及其制备方法以及在神经系统疾病中的应用
CN112898190B (zh) * 2021-02-07 2023-10-24 中国科学院长春应用化学研究所 一种大麻二酚衍生物及其制备方法
WO2025096782A1 (en) * 2023-11-01 2025-05-08 Colorado State University Research Foundation Fluorinated cannabinoid compositions and methods thereof
GB2642523A (en) * 2024-07-12 2026-01-14 Sonas Pharmaceuticals N I Ltd Novel halogenated cannabinoid derivatives

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2012011112A1 (en) * 2010-07-22 2012-01-26 Yissum Research Development Company Of The Hebrew University Of Jerusalem, Ltd. Non psychoactive cannabinoids and uses thereof
ES2894836T3 (es) * 2013-01-08 2022-02-16 Yissum Res Dev Co Of Hebrew Univ Jerusalem Ltd Compuestos de CBD fluorados, composiciones y usos de los mismos

Also Published As

Publication number Publication date
AU2016293387A1 (en) 2018-01-25
WO2017008136A2 (en) 2017-01-19
EP3322411A4 (en) 2019-03-13
CN108024973A (zh) 2018-05-11
CA2992494A1 (en) 2017-01-19
JP2018529636A (ja) 2018-10-11
WO2017008136A3 (en) 2017-11-16
US20190084909A1 (en) 2019-03-21
EP3322411A2 (en) 2018-05-23

Similar Documents

Publication Publication Date Title
ZA202004557B (en) Modulatory polynucleotides
MX2018000515A (es) Compuestos fluorados de cbd, composiciones y usos de los mismos.
PH12018500457A1 (en) New phenoxymethyl derivatives
PH12017501413A1 (en) Substituted nucleoside derivatives useful as anticancer agents
PH12018502535B1 (en) Substituted carbonucleoside derivatives useful as anticancer agents
PH12017502255B1 (en) Nrf2 regulators
MX2023010042A (es) Polinucleotidos moduladores.
PH12018500718A1 (en) Compounds useful as modulators of trpm8
PH12017500408B1 (en) Heteroaryl compounds as btk inhibitors and uses thereof
PH12019550235A1 (en) Kinase inhibitors and uses thereof
PH12016501151A1 (en) Nrf2 regulators
NZ739676A (en) Heteroaryl compounds as irak inhibitors and uses thereof
MX378732B (es) Formas solidas novedosas
AU2015287674B2 (en) Topical antiviral compositions and methods of using the same
MX2016016143A (es) Compuestos de [1,2,4]triazol sustituido.
MX381719B (es) Compuestos cbd fluorados, composiciones y usos de los mismos.
MX2018004674A (es) Moduladores de interacción de sestrina-gator2 y sus usos.
MX2019005855A (es) Formulaciones que se pueden pulverizar.
EP4218736A3 (en) Compositions comprising 15-hepe
MY180844A (en) Solid pharmaceutical compositions comprising biopterin derivatives and uses of such compositions
IN2014CH00840A (es)
MX2016016612A (es) Formulaciones estables de undecanoato de testosterona.
NZ721832A (en) Solid forms of tenofovir
GB2564185A (en) Process for the preparation of derivatives of benzodioxole
MX2018005134A (es) Formulacion de factor viii (fviii).